Detalhe da pesquisa
1.
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 9(1): 53, 2023 Jun 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37344474